APA (7th ed.) Citation

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., . . . Rathkopf, D. E. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The lancet oncology, 16(2), 152-160. https://doi.org/10.1016/S1470-2045(14)71205-7

Chicago Style (17th ed.) Citation

Ryan, Charles J., et al. "Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-naive Men with Metastatic Castration-resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-blind, Placebo-controlled Phase 3 Study." The Lancet Oncology 16, no. 2 (2015): 152-160. https://doi.org/10.1016/S1470-2045(14)71205-7.

MLA (9th ed.) Citation

Ryan, Charles J., et al. "Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-naive Men with Metastatic Castration-resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-blind, Placebo-controlled Phase 3 Study." The Lancet Oncology, vol. 16, no. 2, 2015, pp. 152-160, https://doi.org/10.1016/S1470-2045(14)71205-7.